DouglasWolfMD

PubMed

• Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn's Disease.
  Sarah Harris, Brian G Feagan, Severine Vermeire, Subrata Ghosh, Jim Yan, Chun Wu, Yanhua Hu, Rachel Maddux, Geert D'Haens, Stephen Hanauer, Douglas C Wolf> ;Digestive Diseases and Sciences. 2024 Apr 3
• 2 citations
  Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label ...
  Silvio Danese, Remo Panaccione, Maria T Abreu, David T Rubin, Subrata Ghosh, Axel Dignass, Anita Afzali, Douglas C Wolf, Michael V Chiorean, Severine Vermeire, Anjali ...> ;Journal of Crohn's & Colitis. 2024 Feb 26
• Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses.
  Alessandro Armuzzi, Parakkal Deepak, Miguel Regueiro, Douglas C Wolf, Lucy Akukwe, Harris A Ahmad, Anjali Jain, Marc Kozinn, Hsiuanlin Wu, AnnKatrin Petersen, Lorna Ch...> ;Clinical Gastroenterology and Hepatology. 2023 Nov 30
• 2 citations
  Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER).
  Jean-Frederic Colombel, Ryan C Ungaro, Bruce E Sands, Corey A Siegel, Douglas C Wolf, John F Valentine, Brian G Feagan, Blue Neustifter, Harisha Kadali, Pradeep Nazare...> ;Clinical Gastroenterology and Hepatology. 2023 Sep 22
• Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies.
  William J Sandborn, Jingjing Chen, Krisztina Kisfalvi, Edward V Loftus Jr, Geert D'Haens, Ninfa Candela, Karen Lasch, Douglas C Wolf, Sharif M Uddin, Silvio Danese> ;Crohn's & Colitis 360. 2023 Jul 1
• 29 citations
  Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
  William J Sandborn, Séverine Vermeire, Laurent Peyrin-Biroulet, Marla C Dubinsky, Julian Panes, Andres Yarur, Timothy Ritter, Filip Baert, Stefan Schreiber, Sheldon Sl...> ;Lancet. 2023 Apr 8
• 7 citations
  Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program.
  Brian G Feagan, Stefan Schreiber, Anita Afzali, Florian Rieder, Jeffrey Hyams, Kanthi Kollengode, Jared Pearlman, Vladimir Son, Cecilia Marta, Douglas C Wolf, Geert G ...> ;Contemporary Clinical Trials. 2022 Nov 1
• P031 Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study.
  Bruce Sands, Marc Pondel, Michael Silver, AnnKatrin Petersen, Douglas Wolf, Remo Panaccione, Edward Loftus Jr, Jean-Frederic Colombel, Andreas Sturm, Geert D'Haens> ;The American Journal of Gastroenterology. 2021 Dec 1
• P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis.
  Millie Long, Raymond Cross, Jonathan Calkwood, Marc Pondel, Ashwini Pai, Harris Ahmad, Lorna Charles, Ayanbola Elegbe, AnnKatrin Petersen, James Sheffield, Adil Javed,...> ;The American Journal of Gastroenterology. 2021 Dec 1
• P035 Ozanimod for Moderate-to-Severe Ulcerative Colitis: North American Population Results During Induction and Maintenance in the Phase 3 True North Study.
  David Hudesman, Millie Long, Douglas Wolf, Stephen Hanauer, Subrata Ghosh, AnnKatrin Petersen, Marc Pondel, Michael Silver, Raymond Cross, Brian Feagan> ;The American Journal of Gastroenterology. 2021 Dec 1
• 148 citations
  Ozanimod as induction and maintenance therapy for ulcerative colitis.
  William J. Sandborn, Brian G. Feagan, Geert R. D'Haens, Douglas C. Wolf, Igor Jovanovic, Stephen B. Hanauer, Subrata Ghosh, AnnKatrin Petersen, Steven Y Hua, Ji Hwan L...> ;The New England Journal of Medicine. 2021 Sep 30
• 26 citations
  Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients with Inflammatory Bowel Disease.
  Valeriya Pozdnyakova, Gregory J. Botwin, Kimia Sobhani, John Prostko, Jonathan Braun, Dermot P.B. McGovern, Gil Y. Melmed, Keren L. Appel, Andrea Banty, Edward J. Feld...> ;Gastroenterology. 2021 Aug 12
• 2 citations
  Serum Ustekinumab Concentrations Are Associated With Remission in Crohn's Disease Defined by a Serum-Based Endoscopic Healing Index.
  Margaret Walshe, Krzysztof Borowski, Robert Battat, David Hudesman, Douglas C Wolf, Lauren Okada, Anjali Jain, Mark S Silverberg> ;Crohn's & Colitis 360. 2021 Jul 1
• 44 citations
  Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHST...
  William J. Sandborn, Brian G. Feagan, Stephen B. Hanauer, Severine Vermeire, Subrata Ghosh, Wenzhong J. Liu, Ann Katrin Petersen, Lorna Charles, Vivian Huang, Keith Us...> ;Journal of Crohn's & Colitis. 2021 Jul 5
• 11 citations
  Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice.
  Niels Vande Casteele, Brian G. Feagan, Douglas C. Wolf, Anca Pop, Mohamed Yassine, Sara N. Horst, Timothy E. Ritter, William J. Sandborn> ;Inflammatory Bowel Diseases. 2021 Jul 27
• 75 citations
  Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study
  Brian G. Feagan, William J. Sandborn, Silvio Danese, Douglas C. Wolf, Wenzhong J Liu, Steven Y. Hua, Neil Minton, Allan Olson, Geert R. D'Haens> ;The Lancet. Gastroenterology & Hepatology. 2020 Sep 1
• 4 citations
  Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States.
  Benjamin L Cohen, Zane Gallinger, Christina Ha, Stefan D. Holubar, Jason K. Hou, Jami Kinnucan, Uma Mahadevan, Alan C. Moss, Laura E. Raffals, Miguel Regueiro, Eva Szi...> ;Inflammatory Bowel Diseases. 2020 Aug 20
• 8 citations
  Temporal Improvement of a COVID-19-Positive Crohn's Disease Patient Treated With Bismuth Subsalicylate.
  Douglas C. Wolf, Christine H. Wolf, David T. Rubin> ;The American Journal of Gastroenterology. 2020 Aug 1
• 49 citations
  Capsule Retention in Crohn's Disease: A Meta-analysis
  Shabana F. Pasha, Marco Pennazio, Emanuele Rondonotti, Douglas C. Wolf, Matthew R. Buras, Jörg G. Albert, Stanley A. Cohen, José Cotter, Geert R. D'Haens, Rami Eliakim...> ;Inflammatory Bowel Diseases. 2020 Jan 1
• 20 citations
  Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis.
  Brian G. Feagan, Stefan Schreiber, Douglas C. Wolf, Jeffrey Axler, Arpeat Kaviya, Alexandra James, Rebecca Curtis, Parnia Geransar, Andreas Stallmach, Robert Ehehalt, ...> ;Inflammatory Bowel Diseases. 2019 May 4
• 15 citations
  A simple problem formulation framework to create the right solution to the right problem.
  Alaina Sauve-Ciencewicki, Kathryn P. Davis, Justin McDonald, Tharacad S. Ramanarayanan, Alan Raybould, Douglas C. Wolf, Ted Valenti> ;Regulatory Toxicology and Pharmacology. 2019 Feb 1
• 110 citations
  Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease
  Paul Rutgeerts, Christopher Gasink, Daphne Chan, Yinghua Lang, Paul F. Pollack, Jean-Frederic Colombel, Douglas C. Wolf, Douglas Jacobstein, Jewel Johanns, Philippe Sz...> ;Gastroenterology. 2018 Oct 1
• 92 citations
  Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Devel...
  Rebecca Matro, Christopher F. Martin, Douglas C. Wolf, Samir A. Shah, Uma Mahadevan> ;Gastroenterology. 2018 Sep 1
• 18 citations
  Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From...
  Remo Panaccione, William J. Sandborn, Geert R. D'Haens, Douglas C. Wolf, Sofie Berg, Jen-Fue Maa, J Petersson, Anne M. Robinson> ;Journal of Crohn's & Colitis. 2018 Jul 30
• 5 citations
  Adherence rates and health care costs in Crohn's disease patients receiving certolizumab pegol with and without home health nurse assistance: results from a retrospect...
  Douglas C. Wolf, Srihari Jaganathan, Chakkarin Burudpakdee, Arpamas Seetasith, Robert Low, Edward Lee, Jay Gucky, Mohamed Yassine, David A. Schwartz> ;Patient Preference and Adherence. 2018 May 21
• Join now to see all